Back to Search
Start Over
Treatment of MOG antibody associated disorders: results of an international survey
- Source :
- J Neurol, Journal of Neurology, 267(12), 3565-3577. D. Steinkopff-Verlag, Whittam, D H, Karthikeayan, V, Gibbons, E, Kneen, R, Chandratre, S, Ciccarelli, O, Hacohen, Y, de Seze, J, Deiva, K, Hintzen, R Q, Wildemann, B, Jarius, S, Kleiter, I, Rostasy, K, Huppke, P, Hemmer, B, Paul, F, Aktas, O, Pröbstel, A K, Arrambide, G, Tintore, M, Amato, M P, Nosadini, M, Mancardi, M M, Capobianco, M, Illes, Z, Siva, A, Altintas, A, Akman-Demir, G, Pandit, L, Apiwattankul, M, Hor, J Y, Viswanathan, S, Qiu, W, Kim, H J, Nakashima, I, Fujihara, K, Ramanathan, S, Dale, R C, Boggild, M, Broadley, S, Lana-Peixoto, M A, Sato, D K, Tenembaum, S, Cabre, P, Wingerchuk, D M, Weinshenker, B G, Greenberg, B, Matiello, M, Klawiter, E C, Bennett, J L, Wallach, A I, Kister, I, Banwell, B L, Traboulsee, A, Pohl, D, Palace, J, Leite, M I, Levy, M, Marignier, R, Solomon, T, Lim, M, Huda, S & Jacob, A 2020, ' Treatment of MOG antibody associated disorders : results of an international survey ', Journal of Neurology, vol. 267, no. 12, pp. 3565–3577 . https://doi.org/10.1007/s00415-020-10026-y
- Publication Year :
- 2020
-
Abstract
- Introduction: While monophasic and relapsing forms of myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD) are increasingly diagnosed world-wide, consensus on management is yet to be developed. Objective: To survey the current global clinical practice of clinicians treating MOGAD. Method: Neurologists worldwide with expertise in treating MOGAD participated in an online survey (February–April 2019). Results: Fifty-two responses were received (response rate 60.5%) from 86 invited experts, comprising adult (78.8%, 41/52) and paediatric (21.2%, 11/52) neurologists in 22 countries. All treat acute attacks with high dose corticosteroids. If recovery is incomplete, 71.2% (37/52) proceed next to plasma exchange (PE). 45.5% (5/11) of paediatric neurologists use IV immunoglobulin (IVIg) in preference to PE. Following an acute attack, 55.8% (29/52) of respondents typically continue corticosteroids for ≥ 3 months; though less commonly when treating children. After an index event, 60% (31/51) usually start steroid-sparing maintenance therapy (MT); after ≥ 2 attacks 92.3% (48/52) would start MT. Repeat MOG antibody status is used by 52.9% (27/51) to help decide on MT initiation. Commonly used first line MTs in adults are azathioprine (30.8%, 16/52), mycophenolate mofetil (25.0%, 13/52) and rituximab (17.3%, 9/52). In children, IVIg is the preferred first line MT (54.5%; 6/11). Treatment response is monitored by MRI (53.8%; 28/52), optical coherence tomography (23.1%; 12/52) and MOG antibody titres (36.5%; 19/52). Regardless of monitoring results, 25.0% (13/52) would not stop MT. Conclusion: Current treatment of MOGAD is highly variable, indicating a need for consensus-based treatment guidelines, while awaiting definitive clinical trials.
- Subjects :
- Adult
medicine.medical_specialty
Neurology
MOG, treatment, survey
Azathioprine
Article
MOGAD
Myelin oligodendrocyte glycoprotein
03 medical and health sciences
0302 clinical medicine
Maintenance therapy
Surveys and Questionnaires
Internal medicine
Humans
Medicine
MOG
survey
030212 general & internal medicine
Survey
Child
Autoantibodies
Response rate (survey)
biology
treatment
business.industry
Immunoglobulins, Intravenous
Plasmapheresis
Clinical trial
biology.protein
Myelin-Oligodendrocyte Glycoprotein
Rituximab
Neurology (clinical)
Antibody
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 03405354
- Database :
- OpenAIRE
- Journal :
- J Neurol, Journal of Neurology, 267(12), 3565-3577. D. Steinkopff-Verlag, Whittam, D H, Karthikeayan, V, Gibbons, E, Kneen, R, Chandratre, S, Ciccarelli, O, Hacohen, Y, de Seze, J, Deiva, K, Hintzen, R Q, Wildemann, B, Jarius, S, Kleiter, I, Rostasy, K, Huppke, P, Hemmer, B, Paul, F, Aktas, O, Pröbstel, A K, Arrambide, G, Tintore, M, Amato, M P, Nosadini, M, Mancardi, M M, Capobianco, M, Illes, Z, Siva, A, Altintas, A, Akman-Demir, G, Pandit, L, Apiwattankul, M, Hor, J Y, Viswanathan, S, Qiu, W, Kim, H J, Nakashima, I, Fujihara, K, Ramanathan, S, Dale, R C, Boggild, M, Broadley, S, Lana-Peixoto, M A, Sato, D K, Tenembaum, S, Cabre, P, Wingerchuk, D M, Weinshenker, B G, Greenberg, B, Matiello, M, Klawiter, E C, Bennett, J L, Wallach, A I, Kister, I, Banwell, B L, Traboulsee, A, Pohl, D, Palace, J, Leite, M I, Levy, M, Marignier, R, Solomon, T, Lim, M, Huda, S & Jacob, A 2020, ' Treatment of MOG antibody associated disorders : results of an international survey ', Journal of Neurology, vol. 267, no. 12, pp. 3565–3577 . https://doi.org/10.1007/s00415-020-10026-y
- Accession number :
- edsair.doi.dedup.....c1d243c6172585dcb658a0d3ac7b1c82